AP2255A - Irinotecan preparation. - Google Patents

Irinotecan preparation.

Info

Publication number
AP2255A
AP2255A AP2006003837A AP2006003837A AP2255A AP 2255 A AP2255 A AP 2255A AP 2006003837 A AP2006003837 A AP 2006003837A AP 2006003837 A AP2006003837 A AP 2006003837A AP 2255 A AP2255 A AP 2255A
Authority
AP
ARIPO
Prior art keywords
irinotecan preparation
irinotecan
preparation
Prior art date
Application number
AP2006003837A
Other languages
English (en)
Other versions
AP2006003837A0 (en
Inventor
Keisuke Yoshino
Shigenori Nozawa
Masashi Isozaki
Original Assignee
Yakult Honsha Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Kk filed Critical Yakult Honsha Kk
Publication of AP2006003837A0 publication Critical patent/AP2006003837A0/xx
Application granted granted Critical
Publication of AP2255A publication Critical patent/AP2255A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AP2006003837A 2004-06-01 2005-05-31 Irinotecan preparation. AP2255A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004163742 2004-06-01
PCT/JP2005/009953 WO2005117878A1 (ja) 2004-06-01 2005-05-31 イリノテカン製剤

Publications (2)

Publication Number Publication Date
AP2006003837A0 AP2006003837A0 (en) 2006-12-31
AP2255A true AP2255A (en) 2011-07-21

Family

ID=35462721

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003837A AP2255A (en) 2004-06-01 2005-05-31 Irinotecan preparation.

Country Status (24)

Country Link
US (1) US7846473B2 (es)
EP (1) EP1752150B1 (es)
JP (1) JP4885715B2 (es)
KR (1) KR100889139B1 (es)
CN (1) CN1960729B (es)
AP (1) AP2255A (es)
AR (1) AR049137A1 (es)
AU (1) AU2005249314B2 (es)
BR (1) BRPI0511753A (es)
CA (1) CA2567857C (es)
CR (1) CR8768A (es)
EA (1) EA011612B1 (es)
EC (1) ECSP067041A (es)
ES (1) ES2594621T3 (es)
GE (1) GEP20094620B (es)
IL (1) IL179558A0 (es)
MX (1) MXPA06013874A (es)
NO (1) NO20066074L (es)
NZ (1) NZ551748A (es)
TN (1) TNSN06395A1 (es)
TW (1) TWI362931B (es)
UA (1) UA85099C2 (es)
WO (1) WO2005117878A1 (es)
ZA (1) ZA200610204B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3173073T (lt) 2004-05-03 2025-01-10 Ipsen Biopharm Ltd. Liposomos, skirtos vaistų pristatymui
US20090196917A1 (en) * 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions
CA2724408A1 (en) * 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
WO2010058840A1 (ja) * 2008-11-20 2010-05-27 テルモ株式会社 リポソームからの薬物放出手段および放出性評価法
WO2011066684A1 (zh) * 2009-12-03 2011-06-09 江苏恒瑞医药股份有限公司 伊立替康或盐酸伊立替康脂质体及其制备方法
CN103120645B (zh) * 2009-12-03 2015-03-11 江苏恒瑞医药股份有限公司 伊立替康或盐酸伊立替康脂质体及其制备方法
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
CA2850955C (en) 2011-11-03 2019-11-19 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
KR101842279B1 (ko) * 2012-03-29 2018-03-26 우석대학교 산학협력단 이리노테칸의 안정성증진을 위한 주사제용 조성물
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
AU2013312819A1 (en) * 2012-09-04 2015-03-26 Lauren Sciences Llc Bolaamphiphilic compounds, compositions and uses thereof
EA023079B1 (ru) * 2012-12-24 2016-04-29 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы иринотекана (варианты)
CN104906586A (zh) * 2014-03-10 2015-09-16 中国科学院上海药物研究所 一种盐酸伊立替康复合磷脂组合物、制备方法及其应用
CN105796495B (zh) * 2014-12-29 2020-10-23 南京绿叶制药有限公司 一种盐酸伊立替康脂质体药物组合物及其制备方法
CN105982857B (zh) * 2015-02-09 2019-03-08 湖南科伦药物研究有限公司 一种盐酸伊立替康脂质体组合物及其制备方法
ES2589320B2 (es) * 2015-04-14 2017-06-01 Universidad Politécnica de Madrid Sistema de compartimentación de espacios con membranas enrollables
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
KR101646181B1 (ko) * 2015-08-18 2016-08-05 한양대학교 에리카산학협력단 이리노테칸 함유 이중역상 온도감응성 수용성 겔 조성물
JP7042739B2 (ja) 2015-08-20 2022-03-28 イプセン バイオファーム リミティド 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
TW202400181A (zh) 2015-08-21 2024-01-01 英商益普生生物製藥有限公司 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
EP4647126A3 (en) 2015-10-16 2026-02-11 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
CN110402163A (zh) * 2016-11-02 2019-11-01 易普森生物制药有限公司 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
CN109260155B (zh) 2018-11-05 2021-04-06 杭州高田生物医药有限公司 伊立替康脂质体制剂及其制备与应用
KR102185475B1 (ko) * 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물
CN115364218A (zh) * 2021-05-21 2022-11-22 杭州高田生物医药有限公司 一种特定药脂比的药物组合物在抗肿瘤中的应用
JP7724358B2 (ja) * 2021-10-15 2025-08-15 クンシャン シンユンダ バイオテック カンパニー， リミテッド 抗腫瘍薬を含む組成物、並びにその調製方法及びその使用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001064158A (ja) * 1999-06-25 2001-03-13 Terumo Corp リポソーム
JP2002527466A (ja) * 1998-09-16 2002-08-27 アルザ・コーポレーション リポソーム−閉込めトポイソメラーゼ阻害剤
WO2003041681A2 (en) * 2001-11-13 2003-05-22 Celator Technologies, Inc. Lipid carrier compositions with enhanced blood stability
WO2004087104A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Pharmaceutical compositions containing active agents having a lactone group and transition metal ions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
WO1995008986A1 (en) 1993-09-27 1995-04-06 Smithkline Beecham Corporation Camptothecin formulations
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
EP1190706B1 (en) * 1999-06-25 2009-05-06 Terumo Kabushiki Kaisha Liposomes
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
JP2004501955A (ja) * 2000-06-30 2004-01-22 アイネックス　ファーマシューティカルズ　コーポレイション リポソーム抗新生物薬剤およびその使用
ES2272768T3 (es) 2001-10-03 2007-05-01 Celator Pharmaceuticals Inc Composiciones para la administracion de combinaciones de farmacos.
AU2002331481B2 (en) 2001-10-03 2008-04-24 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
AU2002340670A1 (en) * 2001-11-13 2003-05-26 Celator Technologies, Inc. Lipid carrier compositions and methods for improved drug retention
LT3173073T (lt) 2004-05-03 2025-01-10 Ipsen Biopharm Ltd. Liposomos, skirtos vaistų pristatymui
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002527466A (ja) * 1998-09-16 2002-08-27 アルザ・コーポレーション リポソーム−閉込めトポイソメラーゼ阻害剤
JP2001064158A (ja) * 1999-06-25 2001-03-13 Terumo Corp リポソーム
WO2003041681A2 (en) * 2001-11-13 2003-05-22 Celator Technologies, Inc. Lipid carrier compositions with enhanced blood stability
WO2004087104A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Pharmaceutical compositions containing active agents having a lactone group and transition metal ions

Also Published As

Publication number Publication date
AU2005249314A1 (en) 2005-12-15
US7846473B2 (en) 2010-12-07
CA2567857C (en) 2009-12-22
ES2594621T3 (es) 2016-12-21
IL179558A0 (en) 2007-07-04
EA011612B1 (ru) 2009-04-28
JPWO2005117878A1 (ja) 2008-04-03
AU2005249314B2 (en) 2008-09-11
EP1752150A4 (en) 2012-06-20
CR8768A (es) 2007-08-28
KR20070037440A (ko) 2007-04-04
CN1960729B (zh) 2012-04-11
AP2006003837A0 (en) 2006-12-31
MXPA06013874A (es) 2007-04-25
US20080069868A1 (en) 2008-03-20
UA85099C2 (en) 2008-12-25
EP1752150B1 (en) 2016-08-31
EA200602246A1 (ru) 2007-04-27
CA2567857A1 (en) 2005-12-15
NO20066074L (no) 2007-02-28
CN1960729A (zh) 2007-05-09
TW200600095A (en) 2006-01-01
TNSN06395A1 (en) 2008-02-22
ECSP067041A (es) 2006-12-29
EP1752150A1 (en) 2007-02-14
NZ551748A (en) 2010-02-26
ZA200610204B (en) 2008-01-30
WO2005117878A1 (ja) 2005-12-15
GEP20094620B (en) 2009-02-25
BRPI0511753A (pt) 2008-01-02
TWI362931B (en) 2012-05-01
AR049137A1 (es) 2006-06-28
JP4885715B2 (ja) 2012-02-29
KR100889139B1 (ko) 2009-03-17

Similar Documents

Publication Publication Date Title
AP2255A (en) Irinotecan preparation.
TWI340137B (en) Preparation process
AP2204A (en) 4-phenylamino-quinazolin-6-yl-amides.
DE502005007040D1 (en) Laryngoskop
DE502005007456D1 (en) Nanoemulsionen
DE502004004685D1 (en) Giessmaschine
DE502005009795D1 (en) Modulares gelenkprothesensystem
AP2006003791A0 (en) 1-Heterocyclyl-1,5-dihydro-pyridoÄ3,2-BÜindol-2-ones
GB0415501D0 (en) Forming means
DE502005010653D1 (en) Eiten
GB0408808D0 (en) Synchroniser
PL1763398T3 (pl) Środki do barwienia podłoży
DE502004004917D1 (en) Multiaxialkomplex
DE502005006813D1 (en) Common-rail-injektor
DE502005004945D1 (en) Auto-splice-system
PL367010A1 (en) Anti-recession preparation
ZA200503677B (en) Tea preparation.
GB0414968D0 (en) Novel preparation
GB0415721D0 (en) Novel preparation
AU2909P (en) DT23 Dianella tasmanica
AU300706S (en) Spoon
GB0417533D0 (en) Improved SMPSOGI
GB0414361D0 (en) Privatise easy
GB0416224D0 (en) Easy rockeries
GB0408627D0 (en) C.b.